{"id":1286,"date":"2026-08-26T10:06:48","date_gmt":"2026-08-26T13:06:48","guid":{"rendered":"https:\/\/tirzeclub.com.br\/?p=1286"},"modified":"2026-08-26T15:53:39","modified_gmt":"2026-08-26T18:53:39","slug":"tirzepatida-pre-diabetes","status":"publish","type":"post","link":"https:\/\/tirzeclub.com.br\/en\/tirzepatida-pre-diabetes\/","title":{"rendered":"Tirzepatida and pre-diabetes: what the research shows about the prevention of type 2 diabetes"},"content":{"rendered":"

The pre-diabetes is<\/strong> it is a condition where the glucose is higher than normal, but it still does not meet the criteria used to diagnose type 2 diabetes. It often appears with, and insulin resistance, overweight, abdominal obesity, and other metabolic disorders.<\/p>\n\n\n\n

In the past few years, the Tirzepatida began to attract attention, in this context, because the studies in people with obesity pre-diabetes is<\/strong> they showed a loss of weight, and a significant reduction in the progression to type 2 diabetes.<\/p>\n\n\n\n

The result is a more robust, it came from the extension of the three-year study to SURMOUNT a-1. Among participants who were obese and pre-diabetes at the start of the study, only 1.3% of those treated with Tirzepatida have been diagnosed with type 2 diabetes for 176 weeks, compared to 13.3% in the placebo group.<\/p>\n\n\n\n

These data are important, but they need to be interpreted correctly, the Tirzepatida should not be presented as a \u201ccure\u201d for the pre-diabetes is<\/strong> it is not like a drug for anyone with a glucose slightly higher due to use.<\/p>\n\n\n\n

In this article, you are going to understand what features that change the SURMOUNT-1 is shown as a weight loss participates in effect, and that the follow-up, diet and exercise are still important.<\/p>\n\n\n\n

\n

- Important:<\/strong> this content is purely informative and does not replace evaluation by a doctor. Diagnosis and treatment depend on the exam, medical history, and risk factors of the individual.<\/p>\n<\/blockquote>\n\n\n\n

What is pre-diabetes?<\/h2>\n\n\n\n

The pre-diabetes is<\/strong> occurs when the glucose levels that are above the range considered to be normal, but lower than the values that are used to diagnose diabetes.<\/p>\n\n\n\n

According to the NIDDK, the three tests can be used to identify that condition;<\/p>\n\n\n\n

    \n
  • hemoglobin glicada (A1C) between the 5.7% and 6.4% in<\/strong>;<\/li>\n\n\n\n
  • fasting blood glucose is between 100 to 125 mg\/dL)<\/strong>;<\/li>\n\n\n\n
  • blood sugar levels 2 hours from 140 and 199 mg\/dL<\/strong> after the test, the oral glucose tolerance.<\/li>\n<\/ul>\n\n\n\n

    These tests do not indicate necessarily the same people, and the diagnosis should be performed by a professional.<\/p>\n\n\n\n

    Be altered, it does not mean that the development of type 2 diabetes is not inevitable. The risk can change over time, depending on weight, physical activity, nutrition, genetics, and other health conditions.<\/p>\n\n\n\n

    What is the relationship with insulin resistance?<\/h2>\n\n\n\n

    Insulin resistance is a mechanism that is often behind the rise in glucose.<\/p>\n\n\n\n

    When the muscles, liver and fat tissue, accounting for less and less insulin, your pancreas needs to produce more of this hormone is to keep glucose under control.<\/p>\n\n\n\n

    Over time, your body can't make up for it. After that, the ability of the pancreatic beta cells, it may no longer be sufficient, and the glucose begins to rise.<\/p>\n\n\n\n

    For this reason, pre-diabetes is<\/strong> and insulin resistance, are the concepts that are related but not the same.<\/p>\n\n\n\n

    A person can have, and insulin resistance before you enter the criteria in the laboratory for glucose, as amended.<\/p>\n\n\n\n

    By this stage, it deserves attention.<\/h2>\n\n\n\n

    This condition serves as an important signal to the risk of age.<\/p>\n\n\n\n

    People in this range have a higher chance of developing type 2 diabetes in the future, and also by other factors, such as:<\/p>\n\n\n\n

      \n
    • high blood pressure;<\/li>\n\n\n\n
    • tg high<\/li>\n\n\n\n
    • HDL cholesterol low,<\/li>\n\n\n\n
    • excess abdominal fat;<\/li>\n\n\n\n
    • obesity.<\/li>\n\n\n\n
    • a disease of the liver metabolism.<\/li>\n<\/ul>\n\n\n\n

      This doesn't mean that every person will develop diabetes.<\/p>\n\n\n\n

      To identify at an early stage, creates an opportunity to act on it before the disease is established.<\/p>\n\n\n\n

      Where to Tirzepatida play into this story?<\/h2>\n\n\n\n

      The Tirzepatida acts on the receptors for GIP and GLP-1.<\/p>\n\n\n\n

      The Fda states that the drug improves the sensitivity of insulin and the influence on the secretion of insulin and glucagon in a manner dependent on the glucose, decreases food intake and increases satiety.<\/p>\n\n\n\n

      In addition, it can produce a loss-of-weight-expressive people who meet the criteria for treatment of obesity or being overweight.<\/p>\n\n\n\n

      These effects are especially important because obesity and low insulin sensitivity is strongly related to the pre-diabetes is<\/strong>.<\/p>\n\n\n\n

      The study SURMOUNT-1 and evaluated?<\/h2>\n\n\n\n

      The SURMOUNT-1 was a phase 3, conducted in adults with obesity or overweight, and without type 2 diabetes.<\/p>\n\n\n\n

      In total, there 2.539 participants were included. Of these, 1.032 had pre-diabetes is<\/strong> at the beginning of the study.<\/p>\n\n\n\n

      This sub-group has received Tirzepatida at the doses of 5 mg, 10 mg, or 15 mg, or placebo, for a total of 176 weeks ago, about three years old and four months<\/strong>.<\/p>\n\n\n\n

      After that, there was a period of 17 weeks of treatment to assess what was going on after the meeting.<\/p>\n\n\n\n

      This has long allowed us to see not just weight loss, but it's also how many of the participants developed type 2 diabetes.<\/p>\n\n\n\n

      What happened after that out of 176 weeks ago?<\/h2>\n\n\n\n

      The results have been remarkable.<\/p>\n\n\n\n

      For the 176 weeks of treatment, the diagnosis of type 2 diabetes has occurred of:<\/p>\n\n\n\n

        \n
      • 1,3%<\/strong> the participants in the groups Tirzepatida;<\/li>\n\n\n\n
      • 13,3%<\/strong> the participants in the placebo group.<\/li>\n<\/ul>\n\n\n\n

        The hazard ratio was 0,07<\/strong>, indicating a much smaller risk of progression in the treated group during the period of study.<\/p>\n\n\n\n

        At the same time, the participants had losses, and average weight is:<\/p>\n\n\n\n

          \n
        • 12,3%<\/strong> 5 mg;<\/li>\n\n\n\n
        • 18,7%<\/strong> 10 mg;<\/li>\n\n\n\n
        • 19,7%<\/strong> 15 mg;<\/li>\n\n\n\n
        • 1,3%<\/strong> with placebo.<\/li>\n<\/ul>\n\n\n\n

          These figures show that the observed effects of diabetes occurred in the context of a large reduction in the weight of the body.<\/p>\n\n\n\n

          What happened after the treatment has been discontinued?<\/h2>\n\n\n\n

          In this part of the study, it's especially interesting.<\/p>\n\n\n\n

          After all 176 weeks ago, attendees spent 17 weeks on the treatment assigned to you.<\/p>\n\n\n\n

          At the end of this period, a diagnosis of type 2 diabetes occurred in:<\/p>\n\n\n\n

            \n
          • 2,4%<\/strong> of those who had been Tirzepatida;<\/li>\n\n\n\n
          • 13,7%<\/strong> of those who received a placebo.<\/li>\n<\/ul>\n\n\n\n

            That is, the difference between the groups remained large, but there has been an increase in the number of diagnoses, and after the break.<\/p>\n\n\n\n

            This raises an important idea: the metabolic benefits have been achieved during the treatment, they should not be seen as a permanent protection after the retreat.<\/p>\n\n\n\n

            This means that the Tirzepatida prevent diabetes?<\/h2>\n\n\n\n

            The data show that the in the studied population<\/strong>the treatment was associated with a reduction in very significant to the progression of type 2 diabetes for three years.<\/p>\n\n\n\n

            But the sentence needs to be accompanied by context.<\/p>\n\n\n\n

            The participants were:<\/p>\n\n\n\n

              \n
            • obesity.<\/li>\n\n\n\n
            • change in glycemic;<\/li>\n\n\n\n
            • follow up the inside of a clinical trial;<\/li>\n\n\n\n
            • the intervention of the style of life.<\/li>\n\n\n\n
            • the specific criteria for inclusion.<\/li>\n<\/ul>\n\n\n\n

              Therefore, it is not correct to say that the drug prevents diabetes, any person, or that it should be used with glucose in the highest level.<\/p>\n\n\n\n

              The evidence is strong that the particular group being studied.<\/p>\n\n\n\n

              Tirzepatida that is approved specifically for pre-diabetes?<\/h2>\n\n\n\n

              Not as an indication of alone.<\/p>\n\n\n\n

              In Brazil, the Fda has approved Mounjaro, initially to improve glycemic control in adults with type 2 diabetes. Subsequently, the drug received a nomination for the control of chronic weight in adults who meet the established criteria.<\/p>\n\n\n\n

              On the display to the control of weight, those with a BMI from 27 kg\/m2), may be eligible if there is at least one co-morbidity related to the weight, and the Fda cites pre-diabetes is<\/strong> some of the examples.<\/p>\n\n\n\n

              This is different from saying that anyone with a hemoglobin of glicada 5.8%, for example, indication of control, to use Tirzepatida.<\/p>\n\n\n\n

              The decision depends on the whole picture.<\/p>\n\n\n\n

              The improvement comes only from losing weight?<\/h2>\n\n\n\n

              Losing weight seems to play an important role.<\/p>\n\n\n\n

              An analysis of the SURMOUNT-1 that was published in the year 2025, we evaluated insulin sensitivity and the function of the beta cells of the pancreas.<\/p>\n\n\n\n

              The researchers found that the improvement in insulin sensitivity was mainly associated with the reduction of body weight, although part of the effect, it also seemed directly related to the treatment.<\/p>\n\n\n\n

              The improvements in the measures of the function of beta-cells were more strongly associated with the Tirzepatida.<\/p>\n\n\n\n

              This helps to explain why the improvement of metabolism may involve more than one mechanism.<\/p>\n\n\n\n

              What happens to beta cells?<\/h2>\n\n\n\n

              The beta cells of the pancreas to produce insulin.<\/p>\n\n\n\n

              When there is a resistance to the insulin that is, they will need to work harder to maintain glucose at levels that are appropriate.<\/p>\n\n\n\n

              Over time, some people lose some of this ability to compensate.<\/p>\n\n\n\n

              The analysis in the year 2025, the SURMOUNT-1 found an improvement of parameters related to the function of these cells after 72 weeks of treatment.<\/p>\n\n\n\n

              This does not mean completely regenerates the pancreas, or to cure metabolic disorders.<\/p>\n\n\n\n

              This means that the measures used in the survey have shown a more favorable during the treatment period.<\/p>\n\n\n\n

              Go back to your blood sugar levels normal, that means that the problem is gone for good?<\/h2>\n\n\n\n

              Don't have to be.<\/p>\n\n\n\n

              A person can get out to the range, pre-diabetes is<\/strong> and to get back to the values in the normal range.<\/p>\n\n\n\n

              This is an excellent development.<\/p>\n\n\n\n

              But risk factors may still be present.<\/p>\n\n\n\n

              If there is a recovery of weight, and a sedentary lifestyle, changes that are important in the diet, or the progress of the other changes in the metabolism, the glucose cannot get back up.<\/p>\n\n\n\n

              For this reason, it is more accurate to speak of regression normoglicemia<\/strong> or to improve the state of blood glucose levels than in a \u201cpermanent cure\u201d.<\/p>\n\n\n\n

              \"Refei\u00e7\u00e3o<\/figure>\n\n\n\n

              The power remains important for the treatment of<\/h2>\n\n\n\n

              Yes.<\/p>\n\n\n\n

              This medicine may reduce your appetite, and help facilitate weight loss, but the quality of the food continues to have an influence on the health of metabolism.<\/p>\n\n\n\n

              A good standard can include the following:<\/p>\n\n\n\n

                \n
              • vegetables,<\/li>\n\n\n\n
              • fruit;<\/li>\n\n\n\n
              • the pulses;<\/li>\n\n\n\n
              • protein<\/li>\n\n\n\n
              • whole-grain;<\/li>\n\n\n\n
              • suitable sources of fat:<\/li>\n\n\n\n
              • foods that are minimally processed.<\/li>\n<\/ul>\n\n\n\n

                There is no need for a universal to completely eliminate carbs.<\/p>\n\n\n\n

                The goal is to create a sustainable food that helps in weight control, and glucose.<\/p>\n\n\n\n

                The sugar needs to be banned?<\/h2>\n\n\n\n

                It is not necessary to turn only one kind of food to be responsible for the issue.<\/p>\n\n\n\n

                With the development of type 2 diabetes involves genetics, body weight, visceral fat, physical activity and pancreatic function, power supply and many other factors.<\/p>\n\n\n\n

                The excess number of sugary drinks and foods low in nutritional quality, and can contribute to weight gain, and worsening of metabolism, but it is very different from the claim that consuming sugar is occasionally a \u201ccause of diabetes\u201d.<\/p>\n\n\n\n

                For those with glucose, as amended, the context, and the standard of food is the most important of which is a rule marketing.<\/p>\n\n\n\n

                Can you help?<\/h2>\n\n\n\n

                Yes.<\/p>\n\n\n\n

                Physical activity enhances the utilization of glucose by the muscles, and may increase the sensitivity to insulin.<\/p>\n\n\n\n

                Walking, cycling, and other aerobic activities are useful, and strength training also plays an important role.<\/p>\n\n\n\n

                The muscle is a key tissue involved in glucose uptake.<\/p>\n\n\n\n

                In addition to this, you preserve muscle mass during weight loss it is important for the strength, function, and health of metabolism.<\/p>\n\n\n\n

                Use Tirzepatida does not make the exercise I need.<\/p>\n\n\n\n

                Losing a little weight can help you?<\/h2>\n\n\n\n

                Yes.<\/p>\n\n\n\n

                Studies on the prevention of diabetes is made well in advance of Tirzepatida have already suggested that the changes supported by the weight, and physical activity, may reduce the risk of progression.<\/p>\n\n\n\n

                This means that it is not necessary to imagine that the only losses of 15% and 20% will produce a benefit to age.<\/p>\n\n\n\n

                Smaller reductions may be clinically relevant, depending on the person.<\/p>\n\n\n\n

                The Tirzepatida stands out because it can produce a loss of weight, the larger part of the patients, but the goal should be individualized.<\/p>\n\n\n\n

                Do I need to measure insulin all the time?<\/h2>\n\n\n\n

                No.<\/p>\n\n\n\n

                To monitor the risk of diabetes, or tests such as fasting blood glucose and hb glicada tend to be most commonly used in routine clinical practice.<\/p>\n\n\n\n

                The test is the oral glucose tolerance may also be indicated in certain cases.<\/p>\n\n\n\n

                Serum insulin and calculations, such as HOMA-IR may provide you with additional information on the specific context, but they are not required for all people.<\/p>\n\n\n\n

                The follow-up should be defined by the professional in charge.<\/p>\n\n\n\n

                Hb glicada you can get better quickly?<\/h2>\n\n\n\n

                You can begin to change the course of the first few months, when it comes about the average blood sugar for the last three months.<\/p>\n\n\n\n

                The answer depends on the level of home, weight-loss, nutrition, and other factors.<\/p>\n\n\n\n

                It does not make sense to repeat this test every week.<\/p>\n\n\n\n

                At the appropriate frequency must be set according to the risk, and plan for follow-up.<\/p>\n\n\n\n

                Those who have pre-diabetes, you need medicine?<\/h2>\n\n\n\n

                Not in all cases.<\/p>\n\n\n\n

                For many people, changes in weight, diet, and physical activity are critical, and this may be sufficient to improve glucose.<\/p>\n\n\n\n

                In certain situations, traders may consider further treatment according to weight, age, risk, age, and other factors.<\/p>\n\n\n\n

                The most important thing is to transform the diagnosis in a statement on automatic Tirzepatida.<\/p>\n\n\n\n

                The drug has its own criteria for you to use.<\/p>\n\n\n\n

                Can I use the Tirzepatida only to \u201cturning male\u201d?<\/h2>\n\n\n\n

                Such a decision should not be made in this way.<\/p>\n\n\n\n

                The SURMOUNT-1, showed a major benefit in people with obesity pre-diabetes is<\/strong>but that does not mean that the product is appropriate for anyone concerned with the future.<\/p>\n\n\n\n

                One must consider the following:<\/p>\n\n\n\n